Absci Corp

NASDAQ:ABSIUnited States

Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.

Contact Information

Headquarters

18105 Se Mill Plain BlvdVANCOUVER, WA, United States 98683

Phone

360-949-1041

Fax

302-655-5049

Executives

Chief Executive Officer, Founder, Director

Sean Mcclain

Chief Financial Officer, Chief Business Officer, Treasurer, Director

Zachariah Jonasson

Chief Innovation Officer

Andreas Busch

Lead Independent Director

Karen Mcginnis

Director

Frans Houten